Back to Ovarian Serous Cystadenocarcinoma

Ovarian Serous Cystadenocarcinoma — Clinical Trials

MONDO:00060463 activeLast updated: Mar 20, 2026, 9:46 AM

Trial Landscape

Ovarian Serous Cystadenocarcinoma has an emerging clinical trial program, driven by drug treatment and biological therapy.

Recruiting

Active Trials

By Approach

Drug Treatment3

Biological Therapy1

2 additional trials involve behavioral, dietary, diagnostic, or observational approaches.

By Phase

Phase 1

Phase 2

Sponsor Types

NIH2Academic/Other1

Trial Locations

United States3 trials

Canada1 trial

Singapore1 trial

Trials often recruit across multiple countries, so totals exceed the trial count.

3 Trials

Phase 2Active, Not Recruiting

NCT02101775

Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Jul 2014Est. completion: Mar 2027Updated: Mar 2026

Phase 2Active, Not Recruiting

NCT02122185

Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor:University of Chicago

United StatesStarted: Feb 2015Est. completion: Feb 2027Updated: Jun 2025

Phase 1Active, Not Recruiting

NCT02142803

TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors

Sponsor:National Cancer Institute (NCI)

United StatesStarted: May 2014Est. completion: Oct 2026Updated: Nov 2025

Stay informed about clinical trials for Ovarian Serous Cystadenocarcinoma.

Follow this disease to get updates when trials open, close, or change status.

Follow This Disease — Free

Already have an account? Sign in to manage your watchlists.

Data sourced from ClinicalTrials.gov via Kisho's automated pipeline. Trials refreshed every 4 hours for monitored diseases.

Last sync: March 20, 2026 at 9:46 AM